Home ›
Cervical Cancer Trials ›
NCT06288360
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
Trial Details
NCT ID NCT06288360
Phase PHASE2
Sponsor Tongji Hospital
Status RECRUITING
Cancer Type Cervical Cancer
Interventions Camrelizumab Paclitaxel-albumin Cisplatin radical surgery
Locations (sample) Hefei, Anhui, China|31.86389,117.28083 Beijing, Beijing Municipality, China|39.9075,116.39723 Chongqing, Chongqing Municipality, China|29.56026,106.55771 Lanzhou, Gansu, China|36.05701,103.83987 Nanning, Guangxi, China|22.81667,108.31667
Key Eligibility Criteria
FIGO 2018 stage IB3, IIA2, or IIB/IIIC1r (tumor size\>4cm) cervical cancer and without any treatment (After undergoing gynecological examinations b… Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In principle, the size of the lesio… Histologically confirmed squamous carcinoma, adenocarcinoma (common type) or adenosquamous carcinoma of the cervix; Negative PD-L1 expression on preoperative pathological examination (Combined positive score \< 1);
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Cervical Cancer Trials on Trialify →